A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment

NCT02207244 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

992

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: Guselkumab 100 mg
DRUG: Placebo for guselkumab
DRUG: Adalimumab
DRUG: Placebo for adalimumab

Sponsor

Janssen Research & Development, LLC